Efficacy of Aponeurectomy on the 2-year Recurrence Rate of Dupuytren's

Status Recruiting

Clinical Trial Summary

Dupuytren's disease is a frequent hereditary disease in Northern Europe. It is a degenerative disease affecting the palmar aponeurosis of the hand. It develops a progressive contractile fibrosis which cuts the hypodermic fatty tissue, adheres to the skin and the phalanges, gradually bending the affected rays, resulting in significant functional impotence. Various medical and surgical treatments are available.

Clinical Trial Description

Among these treatments, none to date can eliminate recurrences, which are still too frequent. Open aponeurectomy (consisting of surgical curettage of the fibrotic cords) remains for the moment the reference technique for treating Dupuytren's disease, with recurrences (between 12 and 39%), but less frequent than the needle technique (50 to 85%). Could the addition of adipose tissue in the resection areas of Dupytren's fibrosis reduce the rate of recurrence (by the inhibitory action of ADCs on myofibroblasts) in addition to reconstructing the hypodermis in the cavity left by the resection of the cords and improving the quality of the scars? The investigators insist on the fact that this is a homotopic and homologous adipose tissue graft, in closed circuit without denaturation or adjuvant products. Since, to our knowledge, no other team has used "lipofilling" as an adjuvant treatment to the open resection technique of Dupuytren's cords (aponeurectomy), the investigators first conducted a clinical feasibility and safety study on 70 patients between 2012 and 2017 (currently being published by Springer Editions). The investigators now wish to conduct a prospective comparative study between patients operated by aponeurectomy WITH (experimental group) and WITHOUT (control group) addition of autologous adipose tissue in the resection areas of Dupuytren's cords. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05067764
Study type	Interventional
Source	Elsan
Contact	Elias SAWAYA, MD
Phone	(0)663420278
Email	esawaya.md@gmail.com
Status	Recruiting
Phase	N/A
Start date	June 13, 2022
Completion date	June 1, 2029

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05300893` - Effectiveness of Night Splinting After Percutaneous Needle Fasciotomy in Dupuytren's Contracture	N/A
Recruiting	`NCT04122313` - Post-contracture Release Radiation for Dupuytren's Disease
Completed	`NCT01498640` - Retreatment of Recurrent Dupuytren's Contractures	Phase 4
Completed	`NCT01450397` - MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex	Phase 4
Completed	`NCT03180957` - Repurposing Anti-TNF for Treating Dupuytren's Disease	Phase 2
Completed	`NCT00575458` - Splinting for Dupuytren's Contracture Release	N/A
Completed	`NCT00260429` - Collagenase in the Treatment of Dupuytrens Disease	Phase 3
Completed	`NCT02725528` - Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's	Phase 3
Completed	`NCT02193828` - Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules	Phase 2
Completed	`NCT00954746` - Longterm Observational Study in Subjects Treated With AA4500 in AUX-CC-854, 856, 857, 858 & 859	N/A
Active, not recruiting	`NCT04874870` - Effectiveness of Splinting After Collagenase Injection	Phase 3
Recruiting	`NCT06263699` - Goniometry and Goniometric Measurement on Standardised Images in Dupuytren's Disease
Not yet recruiting	`NCT02294890` - Knee Stiffness in Fibrosis Diathesis	N/A
Completed	`NCT04669704` - Effectiveness of a Tele-Rehabilitation Evidence-based Tablet App for Rehabilitation in Traumatic Bone and Soft Injuries of the Hand, Wrist and Fingers.	N/A
Recruiting	`NCT05440240` - Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture	Phase 4
Active, not recruiting	`NCT01446432` - Validation of Two New Questionnaires for Dupuytren's Disease	N/A
Recruiting	`NCT06281509` - Palmaris Longus Muscle and Dupuytren	N/A
Recruiting	`NCT06321991` - Nodular Shrinking in Dupuytren Disease	Phase 2
Not yet recruiting	`NCT06142929` - Micronerves in Dupuytren and the Impact of Its Dissection on Recurrence
Completed	`NCT01567397` - Registry of Dupuytren's Contracture Treatment Outcomes	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy of Aponeurectomy on the 2-year Recurrence Rate of Dupuytren's Disease — REMEDY

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms